慢性肾臟病市场规模、份额和成长分析（按诊断、治疗方法、给药途径、最终用户和地区划分）－2025-2032年产业预测

预计到 2023 年，全球慢性肾臟病(CKD) 市场规模将达到 141 亿美元，到 2024 年将达到 169.3 亿美元，到 2032 年将达到 733 亿美元，预测期（2025-2032 年）的复合年增长率为 20.1%。

由于糖尿病和高血压盛行率不断上升，全球慢性肾臟病（CKD）市场正经历强劲增长，而糖尿病和高血压正是CKD的主要诱发因素。随着全球人口老化，肾功能的自然衰退进一步加剧了这个问题。患者和医疗保健提供者对CKD的认识不断提高，推动了CKD的早期发现和诊断，进而维持了对治疗药物、介入策略和创新技术治疗方法的高需求。人们对CKD认识的不断提高以及对有效管理方案的迫切需求是市场的主要驱动因素，确保了医疗保健领域在应对这一慢性疾病方面持续增长和拓展的机会。

全球慢性肾臟病市场驱动因素

全球慢性肾臟病市场的主要驱动力是糖尿病和高血压患者群体，这两种疾病是导致肾功能障碍的两大主要原因。随着这些严重慢性疾病盛行率的上升，对治疗方案的需求必然增加，这与慢性肾臟病发病率的上升密切相关。不断增长的患者群体凸显了有效治疗性介入和管理策略的紧迫性，并强调了在更广泛的慢性病管理框架下，需要能够应对肾臟健康复杂性的医疗保健解决方案。因此，这为市场创新和发展提供了巨大的机会。

限制全球慢性肾臟病市场的因素

晚期慢性肾臟病的治疗面临巨大的经济挑战，因为透析和肾臟移植等治疗费用高昂。这种经济负担不仅给病人带来沉重的负担，尤其是在优质医疗保险覆盖范围有限的地区，也影响着国家医疗体系的财政资源。高昂的治疗费用会阻碍患者获得所需的医疗服务，导致患者治疗效果不均，并给医疗预算带来额外的压力。因此，解决这些经济难题对于改善慢性肾臟病病患者的治疗效果，确保所有患者都能公平地获得医疗服务至关重要。

全球慢性肾臟病市场趋势

全球慢性肾臟病市场正经历着向早期诊断和积极干预策略的重大转变。这一发展趋势强调早期发现和管理的重要性，而非仅仅关注终末期治疗，尤其是在高危险群中。世界各地的医疗保健系统日益重视预防措施，推动筛检技术和诊断工具的创新。这一趋势旨在早期识别慢性肾臟病，最终促进能够有效延缓疾病进展的新型疗法的研发。因此，预计该市场将迎来显着成长，体现了肾臟健康管理综合办法。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

慢性肾臟病市场规模（按诊断和复合年增长率划分）（2025-2032 年）

• 市场概览
• 血液检查
  • 血清肌酸酐检测
  • 肾丝球过滤率（GFR）测试
  • 血中尿素氮（BUN）检测
  • 电解质测试
• 尿液检查
  • 尿液检查
  • 24小时尿液收集
  • 尿蛋白检测
  • 尿液白蛋白肌酸酐比值（ACR）
• 影像检查
  • 超音波
  • 电脑断层扫描
  • MRI
  • X射线
• 切片检查
  • 经皮皮肾切片检查
  • 开放式切片检查
  • 腹腔镜切片检查

慢性肾臟病市场规模（依疗法划分）及复合年增长率（2025-2032 年）

• 市场概览
• 药物
• 透析
• 肾臟移植
• ACE抑制剂
• 血液检查
• 其他治疗方法

慢性肾臟病市场规模（依给药途径及复合年增长率划分）（2025-2032 年）

• 市场概览
• 口服
• 静脉注射
• 皮下注射

慢性肾臟病市场规模（依最终用户划分）及复合年增长率（2025-2032 年）

• 市场概览
• 医院和诊所
• 门诊手术中心（ASC）
• 透析中心
• 其他最终用户

慢性肾臟病市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2024 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2024 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2022-2024年营收年比比较

主要企业简介

• AstraZeneca（United Kingdom）
• Amgen Inc.（United States）
• Bayer AG（Germany）
• Fresenius Medical Care（Germany）
• DaVita Inc.（United States）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Baxter International Inc.（United States）
• Novartis AG（Switzerland）
• Johnson & Johnson（United States）
• Pfizer Inc.（United States）
• GlaxoSmithKline plc（GSK）（United Kingdom）
• AbbVie Inc.（United States）
• Boehringer Ingelheim International GmbH（Germany）
• Travere Therapeutics（United States）
• Vera Therapeutics（United States）
• ProKidney（United States）
• Akebia Therapeutics（United States）
• Calliditas Therapeutics AB（Sweden）
• Becton, Dickinson and Company（BD）（United States）
• Renalytix Plc（United Kingdom）

结论与建议

Global Chronic Kidney Disease Market size was valued at USD 14.1 billion in 2023 and is poised to grow from USD 16.93 billion in 2024 to USD 73.3 billion by 2032, growing at a CAGR of 20.1% during the forecast period (2025-2032).

The global chronic kidney disease (CKD) market is experiencing robust growth due to the increasing prevalence of diabetes and hypertension, which are key contributors to CKD. As the global population ages, the natural decline in kidney function exacerbates this issue. Growing awareness among patients and healthcare providers is fostering early identification and diagnosis of CKD, which in turn sustains high demand for therapeutic drugs, intervention strategies, and innovative technological treatments. This heightened recognition of CKD and the urgency for effective management solutions are key market drivers, ensuring continuous growth and expansion opportunities within the healthcare sector addressing this chronic condition.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Chronic Kidney Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Chronic Kidney Disease Market Segments Analysis

Global Chronic Kidney Disease Market is segmented by Diagnosis, Treatment, Route of Administration, End User and region. Based on Diagnosis, the market is segmented into Blood Test, Urine Test, Imaging Test and Kidney Biopsy. Based on Treatment, the market is segmented into Drugs, Dialysis, Kidney Transplant, ACE Inhibitors, Blood Test and Other Treatments. Based on Route of Administration, the market is segmented into Oral, Intravenous and Subcutaneous. Based on End User, the market is segmented into Hospital and Clinics, Ambulatory Surgery Centers (ASCs), Dialysis Centers and Other End-Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Chronic Kidney Disease Market

The global market for chronic kidney disease is primarily driven by individuals suffering from diabetes and hypertension, the two leading contributors to kidney impairment. As the prevalence of these significant chronic conditions intensifies, the demand for treatment options will inevitably rise, correlating with an increased incidence of chronic kidney disease. This growing patient population highlights the urgent need for effective therapeutic interventions and management strategies, emphasizing the urgency for healthcare solutions that address the complexities of kidney health within the broader framework of chronic disease management. Consequently, this presents substantial opportunities for innovation and development within the market.

Restraints in the Global Chronic Kidney Disease Market

The management of advanced chronic kidney disease presents substantial financial challenges, as treatments such as dialysis and kidney transplants entail considerable expenses. This financial strain not only translates to a heavy burden for patients, particularly in regions with limited access to quality health insurance, but it also impacts the fiscal resources of national healthcare systems. The high costs associated with care can create barriers to accessing necessary treatments, leading to disparities in patient outcomes and placing additional stress on healthcare budgets. As a result, addressing these economic constraints is crucial for improving care and ensuring equitable access for all patients facing chronic kidney disease.

Market Trends of the Global Chronic Kidney Disease Market

The global chronic kidney disease market is witnessing a significant shift towards early diagnosis and proactive intervention strategies. This evolving trend emphasizes the importance of early detection and management, particularly for at-risk populations, rather than solely focusing on late-stage treatment. Healthcare systems worldwide are increasingly prioritizing preventive measures, fostering innovations in screening technologies and diagnostic tools. This movement aims to identify chronic kidney disease in its initial stages, ultimately driving the development of novel therapeutic agents designed to slow disease progression effectively. As a result, the market is poised for substantial growth, reflecting a holistic approach to kidney health management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Chronic Kidney Disease Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Blood Test
  • Serum Creatinine Test
  • Glomerular Filtration Rate (GFR) Test
  • Blood Urea Nitrogen (BUN) Test
  • Electrolyte Tests
• Urine Test
  • Urinalysis
  • 24-hour Urine Collection
  • Urine Protein Test
  • Urine Albumin-To-Creatinine Ratio (ACR)
• Imaging Test
  • Ultrasound
  • CT Scan
  • MRI
  • X-ray
• Kidney Biopsy
  • Percutaneous Kidney Biopsy
  • Open Kidney Biopsy
  • Laparoscopic Kidney Biopsy

Global Chronic Kidney Disease Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Drugs
• Dialysis
• Kidney Transplant
• ACE Inhibitors
• Blood Test
• Other Treatments

Global Chronic Kidney Disease Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intravenous
• Subcutaneous

Global Chronic Kidney Disease Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospital and Clinics
• Ambulatory Surgery Centers (ASCs)
• Dialysis Centers
• Other End-Users

Global Chronic Kidney Disease Market Size & CAGR (2025-2032)

• North America (Diagnosis, Treatment, Route of Administration, End User)
  • US
  • Canada
• Europe (Diagnosis, Treatment, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Medical Care (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DaVita Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Travere Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vera Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ProKidney (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akebia Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Calliditas Therapeutics AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Renalytix Plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations